![]() |
|
|
Mineral Bioavailability Laboratory, U.S. Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: zinc status metallothionein zinc-dependent enzymes differential mRNA display yeast genetics
| INTRODUCTION |
|---|
|
|
|---|
| Assessment of marginal zinc status |
|---|
|
|
|---|
Experimental zinc deficiency in humans.
A relatively small number of human zinc depletion-repletion studies
have been reported since the initial report of human zinc deficiency in
the 1960s. The number of subjects studied in these investigations has
been quite limited. Moreover, several zinc depletion-repletion
study designs have been used that could differentially influence study
outcomes. In general, these studies have revealed that it is difficult
to deplete adult humans of a significant amount of body zinc, even when
the dietary zinc intake is quite low. This has led many investigators
to also feed their subjects various inhibitory substances, such as
phytate, which is found in soy-based diets or added directly as
sodium phytate, to help minimize zinc absorption. The remarkable
homeostatic ability of the body allows it to severely limit obligatory
zinc losses from the body. Normally, the quantity of zinc lost in urine
is minimal, only ~0.5 mg/d, and in zinc depletion, urinary losses can
be even less. The major change in obligatory zinc losses in response to
various dietary zinc loads is achieved by altering endogenous fecal
zinc losses (King and Keen, 1994
). Endogenous fecal zinc
is a major regulatory focal point of whole body zinc homeostasis in
both animals and humans. These findings from experimental studies are
in general in accord with the recent report that endogenous zinc
excretion is only ~12 mg/d in apparently healthy young Chinese
women who typically consume ~5 mg zinc/d (Sian et al. 1996
). Thus, assuming there are no other significant zinc
losses from the body, obligatory zinc losses apparently can be
maintained for long periods of time at ~2 mg/d. This may explain why
it has been difficult in human zinc depletion studies to demonstrate
significant effects of feeding low dietary zinc intakes on several
outcome parameters.
Zinc-dependent enzymes.
Because zinc has an important role in many enzymes, human zinc
depletion-repletion studies have investigated whether changes in
some of these enzyme activities might be a marker of zinc status. For
example, Prasad et al. (1978)
fed four adult male
subjects a soy-based, semipurified, zinc-depletion diet
containing 3 mg zinc/d for 612 mo and then repleted them for 23 mo
with 30 mg zinc/d. Measurements of plasma lactic dehydrogenase, plasma
ribonuclease and plasma alkaline phosphatase appeared to show promise
as possible zinc-dependent biomarkers. In a subsequent study by
Baer and King (1984)
, six young men were fed a
semipurified, egg albumenbased diet supplying <0.3 mg Zn/d for 46
wk, until their serum zinc concentrations were <70 µg/dL, and then
they were repleted for 25 wk with zinc. In this study, no effect of
zinc was apparent on serum lactic dehydrogenase, alkaline phosphatase,
ribonuclease or red blood cell
(RBC)3
-aminolevulinic acid dehydrogenase. Ruz et al. (1991)
fed 15 young men 0.6 mg Zn/d for 1 wk and then 4 mg Zn/d for 4 wk,
followed by a 2-wk zinc-repletion period; the authors reported the
lack of an effect of dietary zinc depletion on putative
zinc-responsive enzymes such as plasma angiotensin 1converting
enzyme, purine 5'-nucleotidase,
-D-mannosidase and
alkaline phosphatase. Thus, for whatever reason, human dietary zinc
depletion studies have not identified a reliable zinc-dependent
enzyme marker of zinc deficiency.
Metallothionein.
Intriguing findings concerning the effects of dietary zinc depletion on
metallothionein (MT) have been reported. Grider et al. (1990)
studied seven subjects after a short-term, 8-d
dietary zinc-depletion (0.46 mg Zn/d) period and found that RBC
lysate MT concentrations decreased significantly by ~50% (from 34 to
20 µg/g protein). In a separate group of subjects, RBC MT increased
by 10 d of zinc supplementation with 50 mg Zn/d. In a subsequent
study by this group, Thomas et al. (1992)
showed that
RBC MT was responsive to a 12-d zinc-depletion period when 15 young
men were fed 0.55 mg Zn/d followed by a 30-d zinc-repletion period
with 50 mg Zn/d. Parenthetically, it should be noted that despite the
changes found in RBC MT concentration in response to zinc, no changes
were observed in plasma zinc levels. This may have been due to tissue
breakdown and release of intracellular zinc into plasma. It is
interesting that changes in RBC MT were observed in both of the studies
(Grider et al. 1990
, Thomas et al. 1992
)
that involved the use of severe, but very short-duration (712 d),
zinc-depletion periods that presumably would not result in major
changes in total body zinc stores. Thus, RBC MT may be responsive to a
very labile functional zinc pool and could prove to be a useful marker
of zinc deficiency. The rapidity of response of the MT-sensitive
intracellular zinc pool is further attested to by the rapid changes
reported by this group (Sullivan et al. 1998
) in
monocyte MT mRNA levels in response to short-term zinc
supplementation. Additional study of the potential usefulness of this
measure of zinc status under more chronic conditions of zinc depletion
appears to be warranted at this time.
| Zinc status as a selection criterion in zinc supplementation studies |
|---|
|
|
|---|
An alternative approach to the question of zinc-dependent function could be to select a subject population with suboptimal levels of the biomarker (e.g., growth rate or immune status) of interest and then hypothesize that poor zinc status is responsible for a significant portion of the poor biomarker status and thus will likely change in response to zinc supplementation. This approach has been used extensively in trying to define the role of zinc in the immune response of elderly persons and in growth in children. However, there are several potentially important drawbacks to this approach to the definition of zinc-dependent functions in human populations. For example, the depressed immunity or growth function may have a multifactorial pathogenesis that will obscure the role of zinc in the dysfunction of interest. From the strictly nutritional point of view, it is likely that a population with poor zinc nutriture may also have several other unknown nutritional deficiencies, some of which could significantly limit the responsiveness of the measured biomarker. Another important limitation is that it can be expected that even where zinc does have an important functional role, only those individuals within the study population with suboptimal zinc status will respond to treatment. Because the prevalence of poor zinc status is unknown, the overall effect of zinc treatment can vary considerably from study to study due to a variable number of subjects who are in fact zinc deficient. This results in a highly conflicting body of evidence when all of the studies are examined as a whole. This state of affairs seems to be generally true if one looks at all of the studies that have been published concerning the effects of zinc supplementation on various functional outcomes.
| Possible new approaches to zinc status assessment |
|---|
|
|
|---|
Ferritin model of iron status assessment.
A potentially instructive paradigm concerning the assessment of mineral
status that could act as a goal for work in the area of zinc status
assessment is the measurement of serum ferritin and serum transferrin
receptor concentrations to assess the full range of iron status. Serum
ferritin concentration provides a reliable measure of body iron stores
in most circumstances, although it can be confounded by inflammatory
conditions or during episodes of acute infection (Cook and Finch, 1979
). Serum transferrin receptor has been shown to be
useful as a biomarker of tissue iron deficiency (Flowers et al. 1989
) that is independent of inflammation or the acute phase
response (Skikne et al. 1990
).
Ferritin is a multichain, ubiquitous cellular iron-storage protein
that is translationally regulated according to cellular iron status via
the action of cellular iron-responsive proteins (IRP1 and IRP2)
that bind to a 5' iron-responsive element (IRE) on the ferritin
mRNA (Theil 1998
). Under conditions of cellular iron
surfeit, the iron-loaded IRP dissociates from the mRNA IRE, thus
allowing translation of the protein subunits to occur. Some of the
ferritin protein can be immunologically detected in the serum and has
been shown to reflect body iron stores over a considerable range. Very
low serum ferritin concentrations have been shown to correspond to the
absence of stainable iron in bone marrow and thereby are useful to
identify individuals with low iron stores. The measurement of serum
ferritin concentration has been confirmed to be a good measure of a
wide range of body iron stores, and low serum ferritin can be used as a
marker of depletion of body iron reserves, which precedes the
development of frank iron deficiency, characterized by reduced
hemoglobin synthesis and the development of a microcytic, hypochromic
anemia.
Metallothionein as a measure of zinc status.
MT is an ubiquitous cellular zinc storage protein that may prove to be
a useful measure of zinc status. Grider et al. (1990)
first reported in 1990 that RBC concentrations of MT could be shown to
decrease in young men fed a zinc-deficient diet for several days
and to be rapidly increased after supplementation with 50 mg zinc/d.
Thus, RBC MT concentrations appeared to be a promising measure of zinc
status. Recently, Sullivan et al. (1998)
extended these
earlier observations by examining the expression of MT mRNA in
circulating monocytes from humans. Monocyte MT mRNA measured by a
competitive reverse transcription-polymerase chain reaction assay
responds rapidly to zinc supplementation, resulting in a severalfold
induction of mRNA within 2 d of consumption of a 50 mg/d zinc
supplement. Thus, this novel measure of zinc-induced
transcriptional activity is a sensitive indicator of changes in zinc
status caused by zinc supplementation. However, an important question
that remains is whether RBC MT or monocyte MT mRNA levels are useful in
the detection of marginal zinc deficiency. Because MT is primarily an
intracellular zinc storage protein, the measurement of MT mRNA or MT
protein is likely to not be an ideal measure of marginal zinc
deficiency. On the other hand, it may have significant use as a
selection criterion to eliminate from zinc supplementation studies
subjects who have robust zinc stores. Similarly, the usefulness of
serum ferritin as an index of iron stores becomes limited in the phase
of iron depletion immediately preceding the onset of frank deficiency.
Under these conditions, the expression of this iron storage protein is
quite low, but no obvious iron-responsive functional deficit may be
present. Nevertheless, a high prevalence of truly iron-deficient
(anemic) subjects will be found among subjects with low serum ferritin.
Thus, by analogy, subjects with very low RBC MT concentrations may be
at an increased risk of zinc deficiency.
Serum transferrin receptor and tissue iron deficiency.
The period of early tissue iron depletion in the absence of anemia can
be estimated by the measurement of serum transferrin receptor
concentrations (Skikne et al. 1990
). The synthesis of
ferritin and transferrin receptor reflects cellular iron status but in
reciprocal directions. Like ferritin mRNA, the transferrin receptor
mRNA also contains an IRE that can bind IRP. However, in the case of
the transferrin receptor mRNA, the IRE is 3'. High cellular iron stores
result in a disassociation of the IRP from the 3' IRE in transferrin
receptor mRNA, but in this case the dissociation of IRP from the IRE
results in increased degradation of the transferrin receptor mRNA,
leading in turn to lower levels of transferrin receptor protein. In
contrast, when intracellular iron concentrations are low, the levels of
transferrin receptor mRNA are increased due to increased stabilization
of the mRNA, and more transferrin receptor is synthesized and sent to
the cell surface. More transferrin receptor results in an increased
ability to take up iron-bound transferrin from the circulation and
replenish the depleted cellular iron stores. The increased
concentration of transferrin receptor protein during iron deficiency is
reflected in increased plasma levels of a truncated form of the cell
surface transferrin receptor that can be detected in an
antibody-based assay as a measure of tissue iron depletion
(Skikne et al. 1990
). The search for a functionally
parallel protein involved in regulating cellular zinc homeostasis, such
as a putative cell surface zinc transporter, may be a fruitful approach
to the identification of a potential specific candidate measure of zinc
status.
| Novel insights from genetic studies |
|---|
|
|
|---|
As a possible future investigational strategy, it is important to
consider that many functional proteins have been well conserved during
the evolution of higher multicellular organisms. In this regard, useful
insights into mammalian mineral metabolism, especially for iron and
copper, have already been gained from a better understanding of metal
metabolism in simple eukaryotic organisms, such as the yeast
Saccharomyces cerevisiae (Wood and Han 1999
).
Additional research insights into the regulation of metal homeostasis
in these more simple organisms will undoubtedly have a significant
payoff of a greater understanding of metal regulation in mammals. In
the case of zinc, there are an increasing number of genes that are
being identified that are involved with zinc metabolism (Eide 1998
). In my opinion, two interesting yeast genes,
-zap1 and zrt1, that might have mammalian
counterparts deserve particular scrutiny as possible biomarkers of zinc
status. zrt1 is a yeast gene that codes for a high affinity
zinc transporter (Zhao and Eide 1996
). Presuming a
mammalian counterpart exists, does dietary zinc depletion result in an
up-regulation of the expression of this gene? If so, could a human
zrt homologue be a useful and convenient biomarker of zinc
deficiency? The second yeast gene of interest is zap1
(Zhao et al. 1998
, Zhao and Eide 1997
),
which codes for a transcriptional activator of the zinc transporter
gene zrt. An interesting aspect of zap, at least
in yeast, is that it is positively autoregulated, i.e., increasing
expression of zap results in further up-regulation of
its own expression. Thus, zap might be a sensitive cellular
zinc sensor, wherein small changes in cellular zinc status may result
in significant changes in zap expression that could be used
to monitor cellular zinc status.
Differential mRNA display.
Increasing knowledge of metal homeostasis in simple organisms will
certainly augment our understanding of metal metabolism in higher
organisms and hopefully lead to important insights that will help to
identify useful markers of zinc status. An additional approach to this
problem is the use of differential mRNA display from mammalian tissues.
This technique has the potential of identifying mRNAs in various
tissues that are preferentially up- or down-regulated by zinc
deficiency. Some of these genes may already be known to be regulated by
zinc, but some may represent novel zinc-regulated genes. For
example, Blanchard and Cousins (1996)
recently used this
approach in intestinal tissue from zinc-deficient and
zinc-replete rats to identify a variety of genes that are
differentially regulated by zinc status. Extension of this novel mRNA
expression discovery technique to additional tissues may be fruitful in
identifying potential protein markers of zinc status.
Despite its obvious potential role in the discovery process,
gene-based approaches to identifying potential candidate markers of
marginal zinc deficiency will likely need to be complemented by more
traditional protein-based discovery approaches. Increasing
technical advances in both genomic and "proteomic" (Celis et al. 1998
, Humphery-Smith and Blackstock 1997
)
investigations will hopefully advance our knowledge of cellular zinc
homeostasis and result in the refinement of zinc status assessment
markers. These novel findings will eventually have to be examined in
the context of zinc depletion-repletion studies in humans. The
pathway to better zinc assessment tools will likely continue to be
tortuous. However, the payoff from this effort can be considerable. The
development of better zinc assessment tools will help to define the
important role of zinc status in a variety of important health outcomes
and lead to a more precise definition of the optimal levels of zinc
nutrition for individuals throughout the life cycle.
| FOOTNOTES |
|---|
2 Supported in part by the U.S. Department of Agriculture, Agricultural Research Service (contract number
53-3K06-5-10). The contents of this publication do not necessarily
reflect the views or policies of the U.S. Department of Agriculture,
nor does mention of trade names, commercial products or organizations
imply endorsement by the U.S. government. ![]()
3 Abbreviations: IRE, iron-responsive element; IRP, iron-responsive protein; RBC, red blood cell; MT, metallothionein. ![]()
| REFERENCES |
|---|
|
|
|---|
1. Aggett P. J. The assessment of zinc status: a personal view. Proc. Nutr. Soc. 1991;50:9-17[Medline]
2.
Baer M., King J. Tissue zinc levels and zinc excretion during experimental zinc depletion in young men. Am. J. Clin. Nutr. 1984;39:556-570
3.
Blanchard R. K., Cousins R. J. Differential display of intestinal mRNAs regulated by dietary zinc. Proc. Natl. Acad. Sci. U.S.A. 1996;93:6863-6868
4. Brown K. H., Peerson J. M., Allen L. H. Effect of zinc supplementation on childrens growth: a meta-analysis of intervention trials. Bibl. Nutr. Diet. 1998;54:76-83
5. Celis J. E., Ostergaard M., Jensen N. A., Gromova I., Rasmussen H. H., Gromov P. Human and mouse proteomic databases: novel resources in the protein universe. FEBS Lett 1998;430:64-72[Medline]
6.
Cook J. D., Finch C. A. Assessing iron status of a population. Am. J. Clin. Nutr. 1979;32:2115-2119
7. DiSilvestro R., Cousins R. Physiological ligands for copper and zinc. Annu. Rev. Nutr. 1983;3:261-288[Medline]
8. Eide D. J. The molecular biology of metal ion transport in Saccharomyces cerevisiae. Annu. Rev. Nutr. 1998;18:441-469[Medline]
9. Flowers C. H., Skikne B. S., Covell A. M., Cook J. D. The clinical measurement of serum transferrin receptor. J. Lab. Clin. Med. 1989;114:368-377[Medline]
10.
Grider A., Bailey L. B., Cousins R. J. Erythrocyte metallothionein as an index of zinc status in humans. Proc. Natl. Acad. Sci. U.S.A. 1990;87:1259-1262
11. Humphery-Smith I., Blackstock W. Proteome analysis: genomics via the output rather than the input code. J. Prot. Chem. 1997;16:537-544[Medline]
12. King J., Keen C. Zinc. Shils M. Olson J. Shike M. eds. Modern Nutrition in Health and Disease 1994:214-230 Lea & Febiger Philadelphia, PA.
13. King J. C. Assessment of zinc status. J. Nutr. 1990;120(suppl. 11):1474-1479
14. Mares-Perlman J., Subar A., Block G., Greger J., Luby M. Zinc intake and sources in the US adult population: 19761980. J. Am. Coll. Nutr. 1995;14:349-357[Abstract]
15. Mills C. F. eds. Zinc in Human Biology 1989 Springer-Verlag Berlin/New York, NY.
16. Moynahan E. J. Acrodermatitis enteropathica: a lethal inherited human zinc deficiency disorder. Lancet 1974;2:399-400[Medline]
17. Prasad A. S. Zinc deficiency in sickle cell disease. Prog. Clin. Biol. Res. 1984;165:49-58[Medline]
18.
Prasad A. S. Discovery of human zinc deficiency and studies in an experimental human model. Am. J. Clin. Nutr. 1991;53:403-412
19. Prasad A. S., Halsted J. A., Nadimi M. Syndrome of iron deficiency anemia, hepatosplenomegaly, hypogonadism, dwarfism and geophagia. Am. J. Med. 1961;31:532
20. Prasad A. S., Rabbani P., Abbasii A., Bowersox E., Fox M. R. Experimental zinc deficiency in humans. Ann. Intern. Med. 1978;89:483-490
21.
Ruz M., Cavan K. R., Bettger W. J., Thompson L., Berry M., Gibson R. S. Development of a dietary model for the study of mild zinc deficiency in humans and evaluation of some biochemical and functional indices of zinc status. Am. J. Clin. Nutr. 1991;53:1295-1303
22. Sandstead H. H. Is zinc deficiency a public health problem?. Nutrition 1995;11:87-92[Medline]
23.
Sian L., Mingyan X., Miller L. V., Tong L., Krebs N. F., Hambidge K. M. Zinc absorption and intestinal losses of endogenous zinc in young Chinese women with marginal zinc intakes. Am. J. Clin. Nutr. 1996;63:348-353
24.
Skikne B. S., Flowers C. H., Cook J. D. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990;75:1870-1876
25. Solomons N. W., Cousins R. J. Zinc. Solomons N. W. Rosenberg I. H. eds. Absorption and Malabsorption of Mineral Nutrients 1984:125-198 Alan R. Liss New York, NY.
26.
Sullivan V. K., Burnett F. R., Cousins R. J. Metallothionein expression is increased in monocytes and erythrocytes of young men during zinc supplementation. J. Nutr. 1998;128:707-713
27. Theil E. C. The iron responsive element (IRE) family of mRNA regulators: regulation of iron transport and uptake compared in animals, plants, and microorganisms. Met. Ions Biol. Syst. 1998;35:403-434[Medline]
28. Thomas E. A., Bailey L. B., Kauwell G. A., Lee D. Y., Cousins R. J. Erythrocyte metallothionein response to dietary zinc in humans. J. Nutr. 1992;122:2408-2414
29. Thompson R. P. Assessment of zinc status. Proc. Nutr. Soc. 1991;50:19-28[Medline]
30. Turnlund J. R., Durkin N., Costa F., Margen S. Stable isotope studies of zinc absorption and retention in young and elderly men. J. Nutr. 1986;116:1239-1247
31. Underwood E. Trace Elements in Human and Animal Nutrition 1977 Academic Press New York, NY.
32.
Walravens P. A., Hambidge K. M., Koepfer D. M. Zinc supplementation in infants with a nutritional pattern of failure to thrive: a double-blind, controlled study. Pediatrics 1989;83:532-538
33.
Walravens P. A., Krebs N. F., Hambidge K. M. Linear growth of low income preschool children receiving a zinc supplement. Am. J. Clin. Nutr. 1983;38:195-201
34. Walsh C. T., Sandstead H. H., Prasad A. S., Newberne P. M., Fraker P. J. Zinc: health effects and research priorities for the 1990s. Environ. Health Perspect. 1994;102(suppl. 2):5-46
35. Williams R. An introduction to the biochemistry of zinc. Mills C. eds. Zinc in Human Biology 1989:15-32 Springer-Verlag London.
36.
Wood R., Han O. Recently identified molecular aspects of intestinal iron absorption. J. Nutr. 1999;128:1841-1844
37.
Zhao H., Butler E., Rodgers J., Spizzo T., Duesterhoeft S., Eide D. Regulation of zinc homeostasis in yeast by binding of the ZAP1 transcriptional activator to zinc-responsive promoter elements. J. Biol. Chem. 1998;273:28713-28720
38.
Zhao H., Eide D. The yeast ZRT1 gene encodes the zinc transporter protein of a high-affinity uptake system induced by zinc limitation. Proc. Natl. Acad. Sci. U.S.A. 1996;93:2454-2458
39. Zhao H., Eide D. J. Zap1p, a metalloregulatory protein involved in zinc-responsive transcriptional regulation in Saccharomyces cerevisiae. Mol. Cell. Biol. 1997;17:5044-5052[Abstract]
This article has been cited by other articles:
![]() |
N. M Lowe, K. Fekete, and T. Decsi Methods of assessment of zinc status in humans: a systematic review Am. J. Clinical Nutrition, June 1, 2009; 89(6): 2040S - 2051S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Domellof, O. Hernell, S. A Abrams, Z. Chen, and B. Lonnerdal Iron supplementation does not affect copper and zinc absorption in breastfed infants Am. J. Clinical Nutrition, January 1, 2009; 89(1): 185 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Hodkinson, M. Kelly, H. D. Alexander, I. Bradbury, P. J. Robson, M. P. Bonham, J. M. O'Connor, C. Coudray, J. J. Strain, and J. M. W. Wallace Effect of Zinc Supplementation on the Immune Status of Healthy Older Individuals Aged 55-70 Years: The ZENITH Study J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2007; 62(6): 598 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. M. Osendarp, C. E. West, and R. E. Black The Need for Maternal Zinc Supplementation in Developing Countries: An Unresolved Issue J. Nutr., March 1, 2003; 133(3): 817S - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Grahn, P. G. Paterson, K. T. Gottschall-Pass, and Z. Zhang Zinc and the Eye J. Am. Coll. Nutr., April 1, 2001; 20(2): 106 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hambidge Human Zinc Deficiency J. Nutr., May 1, 2000; 130(5): 1344S - 1349. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||